Pacific Growth Equities initiates coverage with target of 75-90. I guess with a 12 month target. I think we may do better.
The chart looks very good, we may really go up again a whole lot.
I have been reading more on POC and research applications. These will be as big total markets as the clinical immunoassays, and may eventually be quite a bit bigger. With much better margins.
It's bigger than I had thought, and sooner than I had thought. I think Igen has certain advantages over other technologies that seem to assure it of a considerable niche.
to move on this, they may want more money to take this on. So the idea of a Roche buyout of the license may be real, though my safe instincts say keep this license with Roche. But we may be seeing an extraordinary opportunity in pharmacuetical research and POC. I can see so many ways this origen technology can be used. In other industries, this thing can be also very big. On the other hand, it seems that a couple of million shares could be issued as a secondary offering to raise money, and would keep a steadily increasing revenue stream coming.
I have noticed an increase in shorts to over 600,000,,,I think they are making a mistake IMO. (and they have so far). |
